Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920487 | 0.98 | CYP2B6 (0.33) | CYP2B6 | |
| SCHEMBL24110438 | 0.95 | — | — | |
| SCHEMBL9918376 | 0.79 | ALDH1A1 (0.39) | — | |
| SCHEMBL20365521 | 0.76 | — | — | |
| SCHEMBL24176760 | 0.75 | — | — | |
| SCHEMBL18937489 | 0.74 | — | — | |
| SCHEMBL21637941 | 0.74 | KCNH2 (0.32) | — | |
| SCHEMBL24663779 | 0.73 | CYP2B6 (0.34) | CYP2B6 | |
| SCHEMBL23336586 | 0.70 | CYP2B6 (0.38) | CYP2B6 | |
| SCHEMBL22871678 | 0.70 | CYP2B6 (0.38) | CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023226323-A1 | QUINAZOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 天津济坤医药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CYP2B6 2589/4885 |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | CD4, CCR1, RORC | CYP2B6 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.